Evolus, Inc. (EOLS) stock
EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.69+0.06 (+0.90%)
Close on Nov 17, 2026Market cap $441.88MP/E –Yield –
Evolus total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Evolus's total debt was $156.74M at Jun 30, 2026. For fiscal 2025 it was $146.10M, up 20.2% from the year before. The highest annual figure on record is $146.10M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $146.10M | +20.2% |
| FY2024 | Dec 31, 2024 | $121.51M | +65.3% |
| FY2019 | Dec 31, 2019 | $73.51M | – |
| FY2018 | Dec 31, 2018 | $0 | – |
| FY2017 | Dec 31, 2017 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $156.74M | +7.7% |
| Q1 FY2026 | Mar 31, 2026 | $156.41M | +28.7% |
| Q4 FY2025 | Dec 31, 2025 | $146.10M | +97.0% |
| Q3 FY2025 | Sep 30, 2025 | $145.78M | +97.4% |
| Q2 FY2025 | Jun 30, 2025 | $145.48M | +97.9% |
| Q4 FY2024 | Dec 31, 2024 | $121.51M | +66.0% |
| Q2 FY2020 | Jun 30, 2020 | $74.17M | +1.8% |
| Q1 FY2020 | Mar 31, 2020 | $73.84M | +1.8% |
| Q4 FY2019 | Dec 31, 2019 | $73.51M | – |
| Q3 FY2019 | Sep 30, 2019 | $73.18M | +335.8% |
| Q2 FY2019 | Jun 30, 2019 | $72.86M | +342.4% |
| Q1 FY2019 | Mar 31, 2019 | $72.56M | +349.3% |
| Q4 FY2018 | Dec 31, 2018 | $0 | – |
| Q3 FY2018 | Sep 30, 2018 | $16.79M | – |
| Q2 FY2018 | Jun 30, 2018 | $16.47M | – |
| Q1 FY2018 | Mar 31, 2018 | $16.15M | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
See a number that looks wrong?